Wedbush analyst Nick Setyan maintains Dine Brands Global (NYSE:DIN) with a Outperform and lowers the price target from $85 to $80.
Novel Compound Begins Clinical Testing For Potential Treatment Of Multiple Sclerosis
FSD Pharma Inc. (NASDAQ: HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targetting multiple sclerosis.